??????????????????

?? ??

□□□

□□□

□□□

□□□

□□□□□□ II/III□□□□□□

□□□

□□□

□□□□□ Bayesian method□	□□□□□

14. Cui L, Hung HMJ, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics.1999; 55:853-857.

15. Cui L, Zhang L. On the efficiency of adaptive sample size design. Statistics in Medicine.2019;38:933-944.

16. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biometrical Journal.2006; 48:537–555.

17. Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine.2012; 31:4309–4320.

18. Friede T, Stallard Nigel. A comparison of methods for adaptive treatment selection. Biometrical Journal.2008; 50:767–781.

19. Gould AL. Interim analyses for monitoring clinical trials that do not materially affect the Type I error rate. Statistics in Medicine.1992; 14:1039-1051.

20. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika.1988; 75: 800–802.

21. Howard DR, Brown JM, Todd S, Gregory WM. Recommendations on multiple testing adjustment in multi-arm trials with a shared control group. Statistical Methods in Medical Research.2018 27:1513-1530.

22. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics.2011; 10:347–356.

23. Lan KG, DeMets DL. Discrete Sequential Boundaries for Clinical Trials. Biometrika.1983; 70:659–663.

24. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics.1999; 55: 1286–1290.

25. Maca J, Bhattacharya S, Dragalin S. et al. Adaptive Seamless Phase II/III Designs Background, Operational Aspects, and Examples. Drug Information Journal.2006; 40: 463-474.

26. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika.1976; 63:655–660.

27. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Statistics in Medicine.2001; 30:3267- 3284.

28. Müller HH, Schäfer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches. Biometrics.2001; 57:886–891.

29. Müller HH, Schäfer H. A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine.2004; 23:2497–2508.

30. O’Brien PC, Fleming TR. A Multiple Testing Procedure for Clinical Trials. Biometrics.1979; 549–556.

31. Pocock SJ. Group Sequential Methods in the Design and Analysis of Clinical Trials. Biometrika.1977; 64:191–199.

32. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics.1995; 51:1315–1324.

33. Rosenblum M, Van Der Laan MJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika.2011; 98: 845-860.

34. Shih WJ. Sample size re-estimation – a journey for a decade. Statistics in Medicine.2001; 20:515-518.

35. Shih WJ, Li G, Wang Y. Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches. Contemporary Clinical Trials.2016; 47: 40-48.

36. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika.1986; 73:751–754.

37. Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics.2014; 24:168–187.

38. Wang SJ, Hung HMJ, O’Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal.2009; 51:358–374.

39. Wassmer G, Brannath W. Group sequential and confirmatory adaptive designs in clinical trials. Springer,2016.

40. Wu PS, Lin M, Chow SC. On sample size estimation and re-estimation adjusting for variability in confirmatory trials. Journal of Biopharmaceutical Statistics.2016; 26:44-54.

41. Zhang JJ, Blumenthal G, He K, Tang S, Cortazar P, Sridhara R. Overestimation of the effect size in group sequential trials. Clinical Cancer Research.2012; 18: 4872-4876.

42. Zheng J, Chow SC. Criteria for dose-finding in two-stage seamless adaptive design. Journal of Biopharmaceutical Statistics.2019; 29: 908-919.

Revision #2
Created 2025-12-13 02:27:47 UTC by Colin Wang
Updated 2025-12-13 03:14:43 UTC by Colin Wang